Tempus AI Q1 Loss Widens, Revenue Beats

Tempus AI reported adjusted loss of $0.13 per share versus consensus $0.20, while GAAP loss was $0.70 per share.
Revenue rose 36.1% YoY to $348.1 million, slightly above the $345.4 million estimate and up from $255.7 million a year earlier.
Full‑year 2026 revenue guidance lifted to $1.59‑$1.60 billion (~25% growth), matching consensus, while adjusted EBITDA guidance stays around $65 million.
Diagnostics revenue hit $261.1 million (+34.7% YoY) with oncology volume up 28% and MRD testing up ~500% YoY to 6,500 tests.